Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Breast Cancer Clinical Trial

Official title:

Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03058939
• Other study ID #: IRB15-1005
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 2018
• Est. completion date: June 2019

Study information

• Verified date: April 2019
• Source: University of Chicago
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a two-stage phase II study with a single arm design. It will be conducted in women with breast cancer with stages IIA to IIIC (defined by AJCC 2009 classification) of all histological subtypes. All patients will receive 16 doses of paclitaxel; three breast ultrasound tests and tumor pathologic response evaluation will be used to assess the response to treatment.

Description:

Each patient will be assigned one of the following groups: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 8) unknown (not assessable, insufficient data). Patients with a good response to 8 doses of paclitaxel (complete response or partial response that are operable) will receive an additional 8 courses of paclitaxel chemotherapy before surgery and radiotherapy. The overall response for these patients will be assessed by ultrasonography after a total of 16 weeks of Taxol therapy. Patients with poor response (defined as stable disease or progressive disease or partial response inoperable) as best response after eight weekly courses of paclitaxel will receive 8 cycles of weekly PC. The overall response for these patients will also be assessed by ultrasonography after 8 courses of PC therapy. Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up. Patients in response groups 4-8 above will be considered as failing to respond to treatment.

All conclusions will be based on all eligible patients. The schema for the study is presented in Figures 4-1, 4-2 and 4-3. Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time will be classified as having "symptomatic deterioration". Every effort will be made to document the objective progression even after discontinuation of treatment. All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation. Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors ER and PgR (see glossary and section 10.3) and according to the state of primary menopause (see glossary) at the onset of the study. Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 threeweekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.

The study is designed to estimate the RR of breast cancer patients to weekly paclitaxel chemotherapy and to determine the RR to weekly PC combination chemotherapy in patients resistant to or with poor response (including early progression) while on weekly single agent paclitaxel.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2019
• Est. primary completion date: April 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Women ages of 18 to 70 years old.

2. Biopsy-accessible breast tumor of significant size for core needle biopsy (= 2cm).

3. Patients with histologically confirmed carcinoma of the female breast with any or unknown HRs/HER2 status

4. Clinical stages IIA -IIIC. (AJCC 2009) (Appendix A)

5. Chemotherapy-naïve patients (for this malignancy)

6. Performance status: ECOG performance status 0-3 (Appendix B)

7. Non-pregnant and not nursing. Women of childbearing potential must take the pregnancy test and must commit to receive LHRH agonist Zoladex (goserelin) for two years starting from the commencement of the study medications.

8. Required Initial Laboratory Data. Adequate hematologic, renal and hepatic function, as defined by each of the following:

1. Granulocyte = 1,500/µL

2. Platelet count = 100,000/µL

3. Absolute neutrophil count (ANC) = l500/µL

4. Hemoglobin³10g/dL

5. Bilirubin = 1.5 x upper limit of normal

6. SGOT and SGPT < 2.5 x upper limit of normal for patients without liver metastases

7. Creatinine within institutional normal limits or glomerular filtration rate = 30 mL/min/1.73 m2 by CKD EPI equation (see http://mdrd.com/ for calculator)

Exclusion Criteria:

1. Pregnant or lactating women. Women of childbearing potential not using a reliable and appropriate contraceptive method. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.

Patients will agree to continue the use of acceptable form of contraception for 30 days from the date of last drug administration.

2. Patients with brain metastasis.

3. Serious, uncontrolled, concurrent infection(s).

4. Patients who have received more than 4 weeks of tamoxifen therapy for this malignancy. Patient who have received tamoxifen or raloxifene for purposes of chemoprevention (e.g. Breast Cancer Prevention Trial or for other past indications (including previous breast cancer) are eligible. Tamoxifen or raloxifene therapy will be discontinued at least one month before the patient is enrolled on this study.

5. Treatment for other carcinomas within the last 5 years, except non-melanoma skin cancer and treated cervical carcinoma in-situ (CCIS).

6. Participation in any investigational drug study within 4 weeks preceding the start of study treatment.

7. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation including but not limited to chronic or active infection, HIV-positive patient, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled Diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements.

8. Unwillingness to participate or inability to comply with the protocol for the duration of the study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Cancer Stage II
• Breast Cancer Stage III
• Breast Neoplasms

Intervention

Drug:
• Paclitaxel
Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
• Perjeta
Only administered to patients with HER2-positive disease.
• Herceptin SC
Only administered to patients with HER2-positive disease.
• Tamoxifen
Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
• Letrozole
Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
• LHRH agonist
Administered to all premenopausal patients.
• FEC
Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
• Carboplatin
Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).

Locations

Country	Name	City	State
Nigeria	Lagos State University College of Medicine	Ikeja	Lagos State

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

Nigeria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure overall clinical response rate (OCR)	OCR will be calculated as the proportion of patients with an overall response of complete clinical response (CCR) or partial clinical response (PCR), where tumor response is based on change in tumor diameter after treatment.	24 months
Primary	Measure of complete pathologic response (pCR)	The absence of residual invasive disease in the breast and in the axillary lymph nodes at the completion of treatment will be measured.	24 months
Secondary	Number of participants with adverse events	Incidence and severity of adverse drug reactions (AE) and serious adverse drug reactions (SAE) including clinical laboratory values, vital signs, ECGs and dose interruptions.	24 months
Secondary	Time until progression free survival (PFS)		From start date of therapy to the date of first documented disease progression or death from any cause, whichever may come first, assessed up to 100 months
Secondary	Duration of response (DOR)		From first reponse to the date of first documented disease progression, assessed up to 24 months
Secondary	Analysis of changes from baseline using the quality of life (QoL) instrument	The various domains of QoL over time and the changes from baseline using the validated (by the European Organization for Research and Treatment of Cancer (EORTC)) QoL instrument (global and breast module).	From start date of therapy to the date of first documented disease progression or death from any cause, whichever may come first, assessed up to 100 months.
Secondary	To assess the genetic and epigenetic factors associated with breast cancer in Nigeria	Through correlative study of molecular markers and tumor subtypes/tumor biology with patient's characteristics, response to treatment and patients' outcome	From start date of therapy to the date of death from any cause, assessed up to 100 months
Secondary	Blood concentrations of Perjeta before each dose of Perjeta/Herceptin/paclitaxel/PC	To determine the profile of Perjeta given in combination with Herceptin SC, paclitaxel and paclitaxel + carboplatinum	24 months
Secondary	Blood concentrations of Herceptin SC before each dose of Herceptin/paclitaxel/PC	To determine the profile of Herceptin SC given in combination with Perjeta, paclitaxel and PC	24 months
Secondary	Analysis of hormone recepters (ER and PgR) and HER2	To determine the pattern of response to weekly paclitaxel and PC in combination with hormone therapy or with H/Ptz dual anti-HER2 blockade based on status of clinical markers ! Hormone receptors (ER and PgR) and HER2, and other markers.	Through study completion an average of two years